A key member of the executive team at two public biotech life science companies (SIGA and vTv). Focus on creating and implementing the strategy for growth through partnerships, acquisitions, innovative development and expansion of portfolio while maintaining the highest standards of legal and regulatory compliance. Responsible for legal matters supporting FDA approval of TPOXX®, an antiviral treatment for smallpox developed and purchased pursuant to multiple federal government contracts. Helped navigate successful exit from chapter 11 reorganization with debt raise and securities offering. Prior legal experience includes 16-year tenure at a pharma company and 11-year service as a federal prosecutor focused on health care fraud.